Colour enhancement

From PsychonautWiki
(Redirected from Color enhancement)
Jump to navigation Jump to search

Colour enhancement is defined as an intensification of the brightness and vividness of colors in the external environment. During this experience, reds may seem “redder”, greens may seem “greener", and all colors will likely appear much more distinct, complex, and visually intense than they comparatively would be during everyday sober living.[1][2][3][4][5][6][7][8] At higher levels, this effect can sometimes result in seeing colours which are perceived as surreal or seemingly impossible.[3][4]

Colour enhancement is often accompanied by other coinciding effects such as acuity enhancement and pattern recognition enhancement.[1][2] It is most commonly induced under the influence of mild dosages of psychedelic compounds, such as LSD, psilocybin, and mescaline. However, it can also occur to a lesser extent under the influence of certain stimulants and dissociatives such as MDMA, ketamine[9], or 3-MeO-PCP.

Image examples

 Caption
Tree.jpgJapanese Garden by Anonymous
2C-T-21
Chur City in Switzerland.jpgChur, Switzerland by Naps284
2C-T-2
EPT
5F-PB-22
MET
THJ-2201
Memantine
4-HO-MPT
Pramiracetam
Experience:2.5g Syrian rue + 6g Mimosa Hostilis - Becoming God (my second experience with unity)
Experience:~150mg MDA(oral) - a case of mistaken identity
Experience:300µg AL-LAD - Don't worry, because you're everyone!
25I-NBOMe
Omberacetam
DET
Experience:4x 200ug tabs - You do not need to understand
DOM
Efavirenz
Experience:300µg LSD - Togetherness and the Silent Dusk
5-MeO-DiBF
LSM-775
25B-NBOH
Bufotenin
Enhancementofcolour.jpgShowing differences by Chelsea Morgan
1B-LSD
Experience:Mushrooms and Snuff Films -- Trip Report (3.5 grams)
Coluracetam
ALD-52
2C-D
3C-E
JWH-018
PARGY-LAD
Bromo-DragonFLY
Aniracetam
DiPT
Experience:A combination of DOC, 5-MAPB, 5-MeO-DMT, ETH-LAD, Cannabis, Pentedrone
Experience:BK-2C-B - Various experiences
4-AcO-MiPT
DOI
4-AcO-MET
Experience:3 Grams of Mushrooms - Reset on my Life, Experiencing Satori and the Cosmic Perspective
MDEA
Experience: 22mg 2C-B (oral) / 100ug 1P-LSD (sublingual) - My first time tripping alone (2 days in a row)
Experience:60mg 4-AcO-DMT Nonstop Quasi-Orgasmic Objectless Euphoria
4-HO-MET
Piracetam
Mescaline
LSA
Βk-2C-B
Experience:120mg - Garden of The Gods
Escaline
Oxiracetam
Experience:4-AcO-DMT + 200mg Pill
MiPLA
5-MeO-MiPT
2C-I
25I-NBOH
Ayahuasca
LSZ
Methallylescaline
Pregabalin
Experience:2 tabs DOB - My DOB Nightmare
4-HO-DPT
25C-NBOH
1P-LSD
TMA-6
Experience:25mg 3-MeO-PCP - Enhanced film experience
25B-NBOMe
Experience:75mg 3-FMA - Perfect Blend of Euphoria and Functionality
MiPT
Experience:250mg DXM - DXM Itch and Trip Report
4-AcO-DiPT
DPT
Enhancement of colours - woods.jpgThe Woods by Chelsea Morgan
Psilocybin mushrooms
PRO-LAD
ΑMT
4-HO-EPT
Allylescaline
Phenylpiracetam
Experience:300mg DXM + 25mg DMT + Cannabis - A crazy night
5-Hydroxytryptophan
Experience:1mg 25c-NBOMe - Experiment in my room
2C-H
Phenethylamine (compound)
Ibogaine
Experience:Unknown Dose DOC (Insufflated) - Overdosing and Terifying Ego Death
Experience:5.3g psilocybe cubensis - Dimensional Circumstance and the Fabric of Understanding
Experience:4-HO-MiPT / A care free psychedelic getaway
4-HO-DET
5-MeO-DiPT
Psilocin
3-MeO-PCE
Experience:337mg DMT fumarate - A Day With DMT
Proscaline
Experience:3g mimosa / 3g syrian rue - Connecting with my body
Experience:225mg Pregabalin +Cannabis -Bliss and Serenity; a hedonistic evening
Enhancement of colour rose.jpgRose by Chelsea Morgan
Experience:150mg MDMA + 20mg 2C-B - I designed it this way myself
ETH-LAD
JWH-073
Experience:25mg Deschloroketamine - My first time orally dosing DCK
4-AcO-DMT
2C-C
2C-P
Experience: 5-EAPB (60mg) + 2-FMA (20mg) + 4-AcO-DMT (10mg) - Emotional catharsis
6-APB
Selective serotonin reuptake inhibitor
AL-LAD
Paradise island by Xanny.jpgParadise island by Subsentience
GABAergic hallucinogens
Experience: 15mg 2C-B (oral) - A pleasant low-dose evening with Nexus
25N-NBOMe
Chameleon.jpgChameleon by Anonymous.
Amanita muscaria
3-MMC
DMT
Experience:800 seeds LSA - My First Trip Ever
5-MeO-DALT
25D-NBOMe
Experience:3-MeO-PCP - Extreme psychosis
LSD
MPT
2C-E
4-HO-DiPT
TMA-2
DOB
MDA
4-HO-MiPT
DOC
Experience:40mg - Brothermind and the Forest's Hand
Experience: 36mg 4-AcO-DiPT - Truly, one for the psychedelic animals among us
MDAI
2C-T-7
Experience:225ug LSD + 9g cubensis - Galactic Melt and the Meverse
Experience:Unknown dosage / 1 tab DOC - Psychedelia Turned Into Stimulant Psychosis
Experience:1000 Morning Glory seeds - Rediscovering the Self
2C-B-FLY
4-AcO-DET
Experience:3.5g psilocybe cubensis - Relinquishing of Material Chains/Fear and Desolation
Experience:4.5g - The Grand Introduction to Beauty and Fear
Experience:1050 µg 1cP-LSD - The matrix
MDMA
Experience:2C-P (approx. 35mg) - Asymmetrical Terror and the Geometric Sea
1P-ETH-LAD
THJ-018
2C-B
25C-NBOMe
6-APDB
4-FA

Psychoactive substances

Compounds within our psychoactive substance index which may cause this effect include:

... further results

Experience reports

Annectdotal reports which describe this effect with our experience index include:

See also

External links

References

  1. 1.0 1.1 Papoutsis, Ioannis; Nikolaou, Panagiota; Stefanidou, Maria; Spiliopoulou, Chara; Athanaselis, Sotiris (2014). "25B-NBOMe and its precursor 2C-B: modern trends and hidden dangers". Forensic Toxicology. 33 (1): 1–11. doi:10.1007/s11419-014-0242-9. ISSN 1860-8965. 
  2. 2.0 2.1 Bersani, Francesco Saverio; Corazza, Ornella; Albano, Gabriella; Valeriani, Giuseppe; Santacroce, Rita; Bolzan Mariotti Posocco, Flaminia; Cinosi, Eduardo; Simonato, Pierluigi; Martinotti, Giovanni; Bersani, Giuseppe; Schifano, Fabrizio (2014). "25C-NBOMe: Preliminary Data on Pharmacology, Psychoactive Effects, and Toxicity of a New Potent and Dangerous Hallucinogenic Drug". BioMed Research International. 2014: 1–6. doi:10.1155/2014/734749. ISSN 2314-6133. 
  3. 3.0 3.1 Hartman, Alan M.; Hollister, Leo E. (1963). "Effect of mescaline, lysergic acid diethylamide and psilocybin on color perception". Psychopharmacologia. 4 (6): 441–451. doi:10.1007/BF00403349. ISSN 0033-3158. 
  4. 4.0 4.1 Kleinman, J. E.; Gillin, J. C.; Wyatt, R. J. (1977). "A Comparison of the Phenomenology of Hallucinogens and Schizophrenia From Some Autobiographical Accounts*". Schizophrenia Bulletin. 3 (4): 560–586. doi:10.1093/schbul/3.4.560. ISSN 0586-7614. 
  5. . doi:10.3389/Ffnhum.2015.00346.  Missing or empty |title= (help)
  6. Obreshkova, D., Kandilarov, I., Angelova, V. T., Iliev, Y., Atanasov, P., & Fotev, P. S. (2017). PHARMACO-TOXICOLOGICAL ASPECTS AND ANALYSIS OF PHENYLALKYLAMINE AND INDOLYLALKYLAMINE HALLUCINOGENS (REVIEW). PHARMACIA, 64(1), 41-42. http://bsphs.org/wp-content/uploads/2017/04/Angelova.pdf
  7. Abraham, Henry David (1983). "Visual Phenomenology of the LSD Flashback". Archives of General Psychiatry. 40 (8): 884. doi:10.1001/archpsyc.1983.01790070074009. ISSN 0003-990X. 
  8. Baggott, M.J.; Coyle, J.R.; Erowid, E.; Erowid, F.; Robertson, L.C. (2011). "Abnormal visual experiences in individuals with histories of hallucinogen use: A web-based questionnaire". Drug and Alcohol Dependence. 114 (1): 61–67. doi:10.1016/j.drugalcdep.2010.09.006. ISSN 0376-8716. 
  9. Dillon, P (2003). "Patterns of use and harms associated with non-medical ketamine use". Drug and Alcohol Dependence. 69 (1): 23–28. doi:10.1016/S0376-8716(02)00243-0. ISSN 0376-8716.